HC Wainwright & Co. Reiterates Buy on CARISMA Therapeutics, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on CARISMA Therapeutics (NASDAQ:CARM) and maintained an $11 price target for the company's stock.

November 29, 2023 | 11:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Mitchell Kapoor reaffirmed a Buy rating on CARISMA Therapeutics and maintained a price target of $11, indicating a positive outlook for the stock.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst typically instills confidence in investors and can lead to a positive short term impact on the stock price. Given that the price target is maintained and not lowered, it suggests the analyst's continued belief in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100